Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Alfredo De Nardo"'
Autor:
Leonardo De Luca, Carmine Riccio, Alessandro Navazio, Serafina Valente, Manlio Cipriani, Marco Corda, Alfredo De Nardo, Giuseppina Maura Francese, Cosimo Napoletano, Emanuele Tizzani, Loris Roncon, Pasquale Caldarola, Michele Massimo Gulizia, Domenico Gabrielli, Fabrizio Oliva, Furio Colivicchi
Publikováno v:
European Heart Journal Supplements. 25:D312-D322
Patients suffering from acute coronary syndrome (ACS) present a high risk of recurrence and new adverse cardiovascular events after hospital discharge. Elevated plasma LDL-cholesterol (LDL-C) levels have been shown to be a causal factor for the devel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::25db124f5e0f35c0762571fe6d2f1e96
https://doi.org/10.1093/eurheartjsupp/suad100
https://doi.org/10.1093/eurheartjsupp/suad100
Autor:
David, Mocini, Stefania Angela, Di Fusco, Leonardo, De Luca, Pasquale, Caldarola, Manlio, Cipriani, Marco, Corda, Andrea, Di Lenarda, Alfredo, De Nardo, Giuseppina Maura, Francese, Cosimo, Napoletano, Alessandro, Navazio, Carmine, Riccio, Loris, Roncon, Emanuele, Tizzani, Federico, Nardi, Stefano, Urbinati, Serafina, Valente, Michele Massimo, Gulizia, Domenico, Gabrielli, Fabrizio, Oliva, Furio, Colivicchi
Publikováno v:
European Heart Journal Supplements. 24:C278-C288
The appropriateness of prescribing direct oral anticoagulants [dabigatran, rivaroxaban, apixaban, and edoxaban (DOACs)] is regulated on the criteria established in Phase III trials. These criteria are reported in the summary of the product characteri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c62633bef27f4ea1eadd6db9cfcf564
https://doi.org/10.1093/eurheartj/suac015
https://doi.org/10.1093/eurheartj/suac015
Autor:
Leonardo De Luca, Andrea Rubboli, Maddalena Lettino, Marco Tubaro, Sergio Leonardi, Gianni Casella, Serafina Valente, Roberta Rossini, Alessandro Sciahbasi, Enrico Natale, Paolo Trambaiolo, Alessandro Navazio, Manlio Cipriani, Marco Corda, Alfredo De Nardo, Giuseppina Maura Francese, Cosimo Napoletano, Emanuele Tizzani, Federico Nardi, Loris Roncon, Pasquale Caldarola, Carmine Riccio, Domenico Gabrielli, Fabrizio Oliva, Michele Massimo Gulizia, Furio Colivicchi
Publikováno v:
European heart journal supplements : journal of the European Society of Cardiology. 24
Patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) with or without acute coronary syndromes (ACS) represent a subgroup with a challenging pharmacological management. Indeed, if on the one hand, antithrombotic t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2a210aec67192649eadda7aee52596d
https://pubmed.ncbi.nlm.nih.gov/35663586
https://pubmed.ncbi.nlm.nih.gov/35663586
Autor:
Stefania Angela Di Fusco, Edoardo Gronda, Edoardo Mocini, Fabiana Lucà, Irma Bisceglia, Leonardo De Luca, Pasquale Caldarola, Manlio Cipriani, Marco Corda, Alfredo De Nardo, Giuseppina Maura Francese, Cosimo Napoletano, Alessandro Navazio, Carmine Riccio, Loris Roncon, Emanuele Tizzani, Federico Nardi, Stefano Urbinati, Serafina Valente, Michele Massimo Gulizia, Domenico Gabrielli, Fabrizio Oliva, Giuseppe Imperoli, Furio Colivicchi
Publikováno v:
European heart journal supplements : journal of the European Society of Cardiology. 24
Sodium-glucose cotransporter 2 (SGLT2) inhibitors, dapagliflozin, and empagliflozin, first developed as glucose-lowering agents for the treatment of Type 2 diabetes, have been demonstrated to improve prognosis in patients with heart failure and reduc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74d68e9bcafa7d94032f942a9e6ba632
https://pubmed.ncbi.nlm.nih.gov/35602255
https://pubmed.ncbi.nlm.nih.gov/35602255
Autor:
Leonardo, De Luca, Andrea, Rubboli, Maddalena, Lettino, Marco, Tubaro, Sergio, Leonardi, Gianni, Casella, Serafina, Valente, Roberta, Rossini, Alessandro, Sciahbasi, Enrico, Natale, Paolo, Trambaiolo, Alessandro, Navazio, Manlio, Cipriani, Marco, Corda, Alfredo, De Nardo, Giuseppina Maura, Francese, Cosimo, Napoletano, Emanuele, Tizzani, Loris, Roncon, Pasquale, Caldarola, Carmine, Riccio, Domenico, Gabrielli, Fabrizio, Oliva, Michele Massimo, Gulizia, Furio, Colivicchi
Publikováno v:
Giornale italiano di cardiologia (2006). 23(5)
Patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) with or without acute coronary syndromes (ACS) represent a subgroup with a challenging pharmacological management. Indeed, if on the one hand antithrombotic th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::faf78c5a556c3f60478a2027d90b89b4
https://pubmed.ncbi.nlm.nih.gov/35578959
https://pubmed.ncbi.nlm.nih.gov/35578959
Autor:
David, Mocini, Stefania Angela, Di Fusco, Leonardo, De Luca, Pasquale, Caldarola, Manlio, Cipriani, Marco, Corda, Andrea, Di Lenarda, Alfredo, De Nardo, Giuseppina Maura, Francese, Cosimo, Napoletano, Alessandro, Navazio, Carmine, Riccio, Loris, Roncon, Emanuele, Tizzani, Stefano, Urbinati, Serafina, Valente, Michele Massimo, Gulizia, Domenico, Gabrielli, Fabrizio, Oliva, Furio, Colivicchi
Publikováno v:
Giornale italiano di cardiologia (2006). 22(12)
The prescription appropriateness of direct oral anticoagulants (DOACs [dabigatran, rivaroxaban, apixaban, and edoxaban]) is carefully regulated, taking into account the criteria established in phase III trials and listed in the summary of the product
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8ac4bb9caff144a1c9c3a7de27cc6088
https://pubmed.ncbi.nlm.nih.gov/34845405
https://pubmed.ncbi.nlm.nih.gov/34845405